Two States Sue Cord Blood Bank Over False Advertisements

Sarah Kliff and Azeen Ghorayshi / nytimes - The attorneys general of Texas and Arizona contend that Cord Blood Registry, which stores umbilical cord cells, profited from misleading new parents.

AI Summary: Two state attorneys general filed lawsuits alleging a cord‑blood bank made false or misleading claims about the future therapeutic value of stored units. The actions seek consumer remedies and penalties, challenging marketing that regulators say may have led families to pay for services based on overstated promises about potential medical uses.

“Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos

Claudia Boyd-Barrett and Renuka Rayasam and Amanda Seitz / kffhealthnews - Se supone que la agencia que cuida a niños que llegan solos al país deben reunirlos pronto con sus familias o cuidadores. Pero cada vez más los usan como “carnada” para arrestar a los padres.

AI Summary: Gilead struck a deal to acquire Ouro Medicines for roughly $1.68–1.7 billion, securing an immune‑modulating autoimmune program intended to reset pathological immune responses. The transaction combines upfront cash and potential milestones, expanding Gilead’s pipeline and signaling continued industry appetite for bolt‑on buys to chase novel therapeutics.

Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia

esmo - Findings from the RECITE study

AI Summary: A clinical study found romiplostim effective in treating and preventing recurrent persistent chemotherapy‑induced thrombocytopenia, restoring platelet counts and enabling continuation of scheduled cytotoxic therapy. Patients experienced fewer delays and dose reductions, positioning romiplostim as a useful strategy to keep chemo on track—because, apparently, platelet math still runs cancer care.

UK government recommends maximum two hours of screen time for younger children: What the evidence says

medicalxpress - New UK government guidance recommends that screen time for children under two should be avoided, except for shared activities such as video calls. For children aged two to five, a maximum of an hour a day is suggested. The guidance also outlines that watc…

AI Summary: The UK government updated child‑health guidance recommending strict limits on young children’s screen time, citing evidence linking excessive use to delayed development and poorer sleep. The guidance urges parents and caregivers to prioritize interactive, non‑screen activities and age‑appropriate limits while acknowledging modern practicalities for families.

FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong

abcnews - Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs

AI Summary: The FDA issued warnings over promotional materials and public statements related to a cancer drug associated with a biotech entrepreneur, finding claims that could mislead patients and investors. The agency asked the company to correct materials and refrain from unsubstantiated efficacy or safety assertions while oversight and compliance reviews continue.

FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs

Frank Vinluan / medcitynews - Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier. The post FDA Approval for …

AI Summary: Regulators granted Denali accelerated approval for a brain‑penetrant therapy, recognizing promising early efficacy in a rare neurological indication and addressing unmet needs in CNS drug delivery. The pathway requires confirmatory trials to verify clinical benefit while enabling earlier patient access to a novel mechanism targeting central nervous system disease.

FDA approves 1st weekly basal insulin for Type 2 diabetes

Ella Jeffries / beckershospitalreview - The FDA has approved Novo Nordisk’s Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available in the U.S. for adults with Type 2 diabetes. Awiqli is indicated as an adjunct to diet and exercise and is intended to reduce injecti…

AI Summary: The FDA approved the first once‑weekly basal insulin for adults with Type 2 diabetes, providing an alternative to daily injections and aiming to improve adherence and glycemic control. Regulators based the decision on trials showing comparable efficacy and safety to daily basal insulins, potentially reshaping diabetes management.

FDA approves Rocket's gene therapy for ultra-rare immune disease

Lei Lei Wu / endpoints - A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated approval to Rocket Pharma’s gene therapy ...

AI Summary: The FDA granted approval to Rocket’s gene therapy for a pediatric immune disorder, marking the first regulatory ok for this specific treatment class in children and offering a one‑time corrective option for affected patients. The decision opens access while raising expectations for long‑term follow‑up and real‑world safety monitoring.

Cencora acquiring EyeSouth Partners' retina business for $1.1B

fiercehealthcare - EyeSouth Partners' retina specialists will join Cencora's Retina Consultants of America, a management services organization that already boasts the country's largest network of retina centers.

AI Summary: Cencora has agreed to acquire EyeSouth Partners’ retina business for roughly $1.1 billion, strengthening its position in specialty ophthalmology services. The deal transfers a network of retinal care assets and aims to integrate retina-focused clinical operations and distribution under Cencora’s broader eye‑care strategy.

Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows

medicalxpress - New evidence from a Chinese cohort presented at the European Lung Cancer Congress (ELCC) 2026 shows that one-time low-dose computed tomography (LDCT) screening can significantly reduce lung cancer mortality in a non–risk based population, including indivi…

AI Summary: A large population‑based study found organized lung cancer screening reduced mortality even in people who never smoked, demonstrating the benefits of expanded CT screening criteria and systematic outreach. The results suggest screening programs can detect lethal disease earlier across broader risk groups, prompting reconsideration of current eligibility rules.

Justice Department sues NewYork-Presbyterian in second hospital antitrust case this year

Sydney Halleman / healthcaredive - Federal regulators accused the health system of using its market power to force insurers into “all-or-nothing” contracts. The Justice Department filed a similar lawsuit against OhioHealth last month.

AI Summary: The Justice Department filed suit alleging NewYork‑Presbyterian engaged in unfair contracting and anticompetitive practices that harmed hospitals, physicians, and patients by restricting competition and raising prices. The complaint signals intensified federal scrutiny of hospital consolidation and contractual arrangements that may lock out rivals and drive up healthcare costs.

CommonSpirit, Humana reach new nationwide Medicare Advantage contract

Rebecca Pifer Parduhn / healthcaredive - The new agreement will give Humana’s MA members access to CommonSpirit’s doctors and facilities for the next three years, and returns CommonSpirit to Humana’s networks in Colorado and Texas.

AI Summary: CommonSpirit Health and Humana reached a multi-year Medicare Advantage network agreement expanding MA access across multiple states. The deal secures provider participation, stabilizes reimbursement pathways and affects beneficiary enrollment options, aiming to align hospital networks with Humana’s MA plans while smoothing care coordination and payment arrangements.

Scream your way to happiness? Maybe not, but scream clubs promise some relief

medicalxpress - With a gut-wrenching wail that rippled from her body, Amber Walcker joined about a dozen screaming people in West Seattle who let their frustrations float away over the Puget Sound.

AI Summary: Scream clubs tout catharsis and quick emotional relief, but evidence for lasting mental‑health benefits is sparse. Research suggests short‑lived mood boosts largely driven by social bonding and novelty rather than durable therapeutic change. In short: yelling at strangers might feel good for a night, but don’t expect it to replace therapy.

Nadia Care raises $12M to grow Medicaid maternal care

Ngai Yeung / endpoints - A maternal care startup offering virtual and in-person care just raised $12 million in new funding after dropping commercial insurers to focus on Medicaid, Endpoints News learned exclusively. Nadia Care, previously known as Cayaba Care ...

AI Summary: Nadia Care secured $12 million to expand its community‑centered maternal care model, increasing Medicaid‑focused doula and perinatal support services. The funding aims to scale access in underserved areas, bolster nonclinical supports that improve outcomes, and reduce maternal health disparities — because apparently traditional care alone wasn't cutting it.